Home › Companies › INOVIO PHARMACEUTICALS INC. › 2023-2024

INOVIO PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and INOVIO PHARMACEUTICALS INC.’s Form 8-K, filed 2024-05-28 (Item 5.07 on EDGAR). Page generated 04 October 2026.

13Reported items
117Asset managers
404Fund votes
2024-05-21Main meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore INOVIO PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by INOVIO PHARMACEUTICALS INC.

These tallies are INOVIO PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. INOVIO PHARMACEUTICALS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

INOVIO PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-05-21 (Form 8-K, filed 2024-05-28)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Simon X. Benito	3,735,000	--	--	325,511	7,564,931	Majority: yes
Elect Director: Roger D. Dansey, M.D.	3,752,771	--	--	307,740	7,564,931	Majority: yes
Elect Director: Ann C. Miller, M.D.	3,451,907	--	--	608,604	7,564,931	Majority: yes
Elect Director: Jacqueline E. Shea, Ph.D.	3,812,988	--	--	247,523	7,564,931	Majority: yes
Elect Director: Jay P. Shepard	3,760,672	--	--	299,839	7,564,931	Majority: yes
Elect Director: David B. Weiner, Ph.D.	3,819,190	--	--	241,321	7,564,931	Majority: yes
Elect Director: Wendy L. Yarno	3,106,384	--	--	954,127	7,564,931	Majority: yes
Elect Director: Lota S. Zoth	3,448,595	--	--	611,916	7,564,931	Majority: yes
Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024	11,107,788	440,795	76,859	--	0	Majority: yes
Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement	3,001,768	946,999	111,744	--	7,564,931	Majority: yes

Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-05-28 — read the filing on EDGAR.

INOVIO PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-01-12 (Form 8-K, filed 2024-01-12)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: Reverse Stock Split Proposal	96,534,629	48,857,255	874,089	--	--	Passed
Proposal 2: Adjournment Proposal	106,842,257	37,097,854	2,325,862	--	--	Passed

Source: INOVIO PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-01-12 — read the filing on EDGAR.

How asset managers voted at the INOVIO PHARMACEUTICALS INC. 2023-2024 meetings

Each item below shows how the 117 asset managers that disclosed a INOVIO PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INOVIO PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 9 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%AGAINST 24%

FOR: 3,001,768AGAINST: 946,999

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 3,001,768 for, 946,999 against, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 12% for, 4% against (15% of the company cast a for/against vote).

The 106 asset managers below cast 92% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 92%8%

FOR: 92.1%AGAINST: 7.9%

Largest asset managers voting on “To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive offi” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Baron Financial Group, LLC	4,100,000	0	For
Vanguard	1,387,210	0	For
BlackRock	246,029	2,660	For
Renaissance	0	191,880	Against
State Street	88,681	0	For
Fidelity	9,257	62,912	Against
GEODE CAPITAL MANAGEMENT, LLC	0	66,838	Against
Northern Trust	24,728	0	For
Charles Schwab	0	22,150	Against
American Century	0	18,872	Against
PNC BANK, NATIONAL ASSOCIATION	0	17,916	Against
JACOBS LEVY EQUITY MANAGEMENT, INC	0	16,497	Against
T. Rowe Price	0	12,499	Against
HighTower Advisors, LLC	0	12,118	Against
Two Sigma	0	11,983	Against
CIBC Private Wealth Group LLC	0	10,358	Against
STIFEL NICOLAUS & CO INC \MO\	0	7,854	Against
Corient Private Wealth LLC	0	6,813	Against
OMERS ADMINISTRATION Corp	0	6,400	Against
Amplify ETF Trust	5,876	0	For
PRINCIPAL GLOBAL INVESTORS	0	4,938	Against
Principal Exchange-Traded Funds	0	4,938	Against
BALYASNY ASSET MANAGEMENT L.P.	0	4,450	Against
Dimensional	0	4,016	Against
Nationwide	0	2,776	Against

Showing the 25 largest of 106 asset managers. See all 106 in the interactive database.

2. To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio ranging from 1-for 10 shares up to a ratio of 1-for 50 shares, which ratio will be selected by the Company's Board of Directors and set forth in a public announcement.

CAPITAL STRUCTURECompany result: Passed

Meeting held 2024-01-12.

Combines 3 wordings of this item as funds reported it.

66% Passed · of votes cast

FOR 66%AGAINST 34%

FOR: 96,534,629AGAINST: 48,857,255

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 1: Reverse Stock Split Proposal”): 96,534,629 for, 48,857,255 against — passed, per its Form 8-K filed 2024-01-12 (Item 5.07). Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 13 asset managers below cast 100% of the shares they voted on this item FOR (21,351,918 for, 0 against).

FOR 100%

FOR: 21,351,918 (100.0%)

Largest asset managers voting on “To approve and adopt an amendment to the Company's Amended and Restated Certificate of Incorporation to effect” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	19,639,916	For
BlackRock	902,050	For
Fidelity	235,732	For
Invesco	157,750	For
Charles Schwab	132,910	For
Legg Mason	93,972	For
Amplify ETF Trust	77,447	For
Principal Exchange-Traded Funds	57,651	For
Victory Capital	29,100	For
ProShares	16,671	For
AIG/SunAmerica	5,000	For
Guggenheim	2,464	For
Nationwide	1,255	For

3. To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1.

CORPORATE GOVERNANCECompany result: Passed

Meeting held 2024-01-12.

Combines 2 wordings of this item as funds reported it.

74% Passed · of votes cast

FOR 74%AGAINST 26%

FOR: 106,842,257AGAINST: 37,097,854

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Adjournment Proposal”): 106,842,257 for, 37,097,854 against — passed, per its Form 8-K filed 2024-01-12 (Item 5.07). Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 13 asset managers below cast 100% of the shares they voted on this item FOR (21,351,918 for, 0 against).

FOR 100%

FOR: 21,351,918 (100.0%)

Largest asset managers voting on “To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to so” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	19,639,916	For
BlackRock	902,050	For
Fidelity	235,732	For
Invesco	157,750	For
Charles Schwab	132,910	For
Legg Mason	93,972	For
Amplify ETF Trust	77,447	For
Principal Exchange-Traded Funds	57,651	For
Victory Capital	29,100	For
ProShares	16,671	For
AIG/SunAmerica	5,000	For
Guggenheim	2,464	For
Nationwide	1,255	For

4. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 3,451,907WITHHELD: 608,604

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 3,451,907 for, 608,604 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 13% for, 2% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,448,418 for, 0 against).

FOR 98%

FOR: 1,448,418 (98.0%)ABSTAIN: 29,838 (2.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	1,379,630	0	For
Fidelity	62,912	0	For
Charles Schwab	0	11,075	Abstain
American Century	0	9,436	Abstain
Amplify ETF Trust	5,876	0	For
Principal Exchange-Traded Funds	0	4,938	Abstain
Nationwide	0	2,776	Abstain
Invesco	0	1,033	Abstain
John Hancock	0	375	Abstain
Guggenheim	0	205	Abstain

5. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 3,819,190WITHHELD: 241,321

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 3,819,190 for, 241,321 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 15% for, 1.0% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,478,256 for, 0 against).

FOR 100%

FOR: 1,478,256 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	1,379,630	For
Fidelity	62,912	For
Charles Schwab	11,075	For
American Century	9,436	For
Amplify ETF Trust	5,876	For
Principal Exchange-Traded Funds	4,938	For
Nationwide	2,776	For
Invesco	1,033	For
John Hancock	375	For
Guggenheim	205	For

6. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 3,812,988WITHHELD: 247,523

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 3,812,988 for, 247,523 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 15% for, 1.0% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,478,256 for, 0 against).

FOR 100%

FOR: 1,478,256 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	1,379,630	For
Fidelity	62,912	For
Charles Schwab	11,075	For
American Century	9,436	For
Amplify ETF Trust	5,876	For
Principal Exchange-Traded Funds	4,938	For
Nationwide	2,776	For
Invesco	1,033	For
John Hancock	375	For
Guggenheim	205	For

7. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 3,760,672WITHHELD: 299,839

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jay P. Shepard”): 3,760,672 for, 299,839 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 15% for, 1% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,478,256 for, 0 against).

FOR 100%

FOR: 1,478,256 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	1,379,630	For
Fidelity	62,912	For
Charles Schwab	11,075	For
American Century	9,436	For
Amplify ETF Trust	5,876	For
Principal Exchange-Traded Funds	4,938	For
Nationwide	2,776	For
Invesco	1,033	For
John Hancock	375	For
Guggenheim	205	For

8. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 3,448,595WITHHELD: 611,916

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lota S. Zoth”): 3,448,595 for, 611,916 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 13% for, 2% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,449,451 for, 0 against).

FOR 98%

FOR: 1,449,451 (98.1%)ABSTAIN: 28,805 (1.9%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	1,379,630	0	For
Fidelity	62,912	0	For
Charles Schwab	0	11,075	Abstain
American Century	0	9,436	Abstain
Amplify ETF Trust	5,876	0	For
Principal Exchange-Traded Funds	0	4,938	Abstain
Nationwide	0	2,776	Abstain
Invesco	1,033	0	For
John Hancock	0	375	Abstain
Guggenheim	0	205	Abstain

9. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 3,752,771WITHHELD: 307,740

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 3,752,771 for, 307,740 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 14% for, 1% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,478,256 for, 0 against).

FOR 100%

FOR: 1,478,256 (100.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	1,379,630	For
Fidelity	62,912	For
Charles Schwab	11,075	For
American Century	9,436	For
Amplify ETF Trust	5,876	For
Principal Exchange-Traded Funds	4,938	For
Nationwide	2,776	For
Invesco	1,033	For
John Hancock	375	For
Guggenheim	205	For

10. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 3,735,000WITHHELD: 325,511

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Simon X. Benito”): 3,735,000 for, 325,511 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 14% for, 1% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,464,407 for, 0 against).

FOR 99.0%

FOR: 1,464,407 (99.1%)ABSTAIN: 13,849 (0.9%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	1,379,630	0	For
Fidelity	62,912	0	For
Charles Schwab	11,075	0	For
American Century	9,436	0	For
Amplify ETF Trust	0	5,876	Abstain
Principal Exchange-Traded Funds	0	4,938	Abstain
Nationwide	116	2,660	Abstain
Invesco	1,033	0	For
John Hancock	0	375	Abstain
Guggenheim	205	0	For

11. To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 3,106,384WITHHELD: 954,127

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 3,106,384 for, 954,127 withheld, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 12% for, 4% withheld (16% of the company cast a for/withheld vote).

The 10 asset managers below cast 100% of the shares they voted on this item FOR (1,448,418 for, 0 against).

FOR 98%

FOR: 1,448,418 (98.0%)ABSTAIN: 29,838 (2.0%)

Largest asset managers voting on “To elect the following directors to serve for a term ending upon the 2025 Annual Meeting of Stockholders and u” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	1,379,630	0	For
Fidelity	62,912	0	For
Charles Schwab	0	11,075	Abstain
American Century	0	9,436	Abstain
Amplify ETF Trust	5,876	0	For
Principal Exchange-Traded Funds	0	4,938	Abstain
Nationwide	0	2,776	Abstain
Invesco	0	1,033	Abstain
John Hancock	0	375	Abstain
Guggenheim	0	205	Abstain

12. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2024-05-21.

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 11,107,788AGAINST: 440,795

INOVIO PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31,”): 11,107,788 for, 440,795 against, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 25,910,701 outstanding shares: 43% for, 2% against (45% of the company cast a for/against vote).

The 10 asset managers below cast 99.6% of the shares they voted on this item FOR (1,472,380 for, 5,876 against).

FOR 99.6%

FOR: 1,472,380 (99.6%)AGAINST: 5,876 (0.4%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	1,379,630	0	For
Fidelity	62,912	0	For
Charles Schwab	11,075	0	For
American Century	9,436	0	For
Amplify ETF Trust	0	5,876	Against
Principal Exchange-Traded Funds	4,938	0	For
Nationwide	2,776	0	For
Invesco	1,033	0	For
John Hancock	375	0	For
Guggenheim	205	0	For

13. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-05-21.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (77 for, 0 against).

FOR: 77 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at INOVIO PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
GRIMES & COMPANY, INC.	65	0	0	0	For
PEDDOCK CAPITAL ADVISORS, LLC	12	0	0	0	For

Largest INOVIO PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of INOVIO PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 25,910,701 shares outstanding at the time of that meeting.

Top INOVIO PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Baron Financial Group, LLC	15.82%
2	Vanguard	5.35%
3	BlackRock	0.96%
4	Renaissance	0.74%
5	State Street	0.34%
6	Fidelity	0.28%
7	GEODE CAPITAL MANAGEMENT, LLC	0.26%
8	Northern Trust	0.10%
9	Charles Schwab	0.09%
10	American Century	0.07%

Reported INOVIO PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

INOVIO PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	10.47%	13F
Morgan Stanley	3.04%	13F
BlackRock	1.93%	13F
Renaissance Technologies	1.74%	13F
Millennium Management	1.03%	13F
Geode Capital	0.97%	13F
State Street	0.34%	13F
Citadel Advisors	0.29%	13F
JPMorgan Chase	0.25%	13F
Goldman Sachs	0.21%	13F

Percentages above are of 25,910,701 shares outstanding, as reported by INOVIO PHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-10 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INOVIO PHARMACEUTICALS INC.’s 10-Q dated 2024-05-10. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At INOVIO PHARMACEUTICALS INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held 2024-01-12 and 2024-05-21), 117 asset managers reported how they voted in their SEC Form N-PX filings, covering 404 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2024-05-21 — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 76% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: INOVIO PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-28.

INOVIO PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.